Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERAS-402 in BCG-vaccinated adults
NCT02430506Phase 1Completed
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Sep 2008
- Primary completion
- Jun 2009
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AERAS-402 in Tuberculosis (TB), sponsored by Aeras Global Vaccine Foundation. Primary endpoint: Safety of AERAS-402 at 182 days. Started Sep 2008; status: completed.
02
Drugs
AERAS-402
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02430506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02430506.